NCT07568535: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease
- State
- Not started
- Phase
- Phase 3
- People
- 180 planned
- Started
- 31 Aug 2026
- Primary completion
- 28 Feb 2028
- Arms
- Remestemcel-L-rknd
- Results
- None posted
- 5 May 2026: Trial registered